Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33 results about "Endotoxin shock" patented technology

Endotoxin shock. Etymology: Gk, endon, within, toxikon, poison; Fr, choc. a septic shock in response to the release of endotoxins produced by gram-negative bacteria. The toxin is released on the death of the bacterial cell, especially Escherichia coli.

Medicinal compositions

Medicinal compositions for treating or preventing diabetes, rheumatoid, diseases wherein inflammation should be inhibited, diseases wherein alpha-glycosidase should be inhibited, diseases wherein the synthesis of prostaglandin should be inhibited, diseases wherein endotoxin shock should be inhibited, diseases wherein the production of interleukin should be inhibited, diseases wherein the production of heme oxygenase should be induced, and diseases wherein the production of tumor necrosis factor or carcinogenesis should be inhibited, which contain as the active ingredient at least one compound selected from the group consisting of 3,6-anhydrogalactopyranose represented by formula (I), its aldehyde, its hydrate and 2-O-methylated derivatives and 2-O-sulfated derivatives thereof.
Owner:TAKARA HOLDINGS

Matrix metal proteinase-2 polypeptide inhibitors and application thereof

The invention relates to the field of medicine, and particularly relates to polypeptides capable of inhibiting matrix metal proteinase-2 and tumor necrosis factor liberase and relieving damage of acute inflammation response on organisms. The sequence of the polypeptide is Pro-Thr-Thr-Asn-Arg which is a brand-new sequence. The inhibitors can inhibit the activities of the matrix metal proteinase-2 and tumor necrosis factor liberase in vitro on the 1 micromole level, and increase the survival rate of endotoxin shock mice in an in-vivo test, thereby having potential new drug development value.
Owner:QINGDAO MUNICIPAL HOSPITAL

Application of chitosan oligosaccharide in preparation of medicines for preventing and treating endotoxemia/bacteremia

The invention relates to biological medicines, in particular to an application of chitosan oligosaccharide in preparation of medicines for preventing and treating endotoxemia / bacteremia. The chitosan oligosaccharide can inhibit the secretion of inflammatory factors to prevent and treat endotoxin shock, i.e. the chitosan oligosaccharide can be further used for preparing medicines for preventing and treating endotoxemia. In the invention, the cell experiment shows that the chitosan oligosaccharide can inhibit the secretion of inflammatory cytokines caused by lipopolysaccharide (LPS). The animal experiment shows that the chitosan oligosaccharide can obviously improve the survival rate of a mouse with endotoxemia, inhibit the secretion of inflammatory factors TNF (tumor necrosis factor)-alpha of the mouse and inhibit the secretion of inflammatory factors IL-1beta of a macrophage strain RAW264.7 of the mouse.
Owner:DALIAN GLYCOBIO

Tumor necrosis factor-alpha polypeptide inhibitors and application thereof

The invention relates to tumor necrosis factor-alpha polypeptide inhibitors and application thereof. The invention relates to the field of medicine, and particularly relates to polypeptides capable of inhibiting matrix metal proteinase-2 and tumor necrosis factor liberase and relieving damage of acute inflammation response on organisms. The sequence of the polypeptide is Pro-Thr-Thr-Asn-Arg which is a brand-new sequence. The inhibitors can inhibit the activities of the matrix metal proteinase-2 and tumor necrosis factor liberase in vitro on the 1 micromole level, and increase the survival rate of endotoxin shock mice in an in-vivo test, thereby having potential new drug development value.
Owner:CHANGZHOU ADAM BIOTECH

Application of mycoepoxydiene nicotinic acids derivatives in preparation process of pro-inflammatory mediator inhibitors

The invention discloses the application of mycoepoxydiene nicotinic acids derivatives in the preparation process of pro-inflammatory mediator inhibitors, and relates to the mycoepoxydiene nicotinic acids derivatives 4-NDM (4-N Dodecyl Mercaptan). The provided application of the mycoepoxydiene nicotinic acids derivatives in the preparation process of the pro-inflammatory mediator inhibitors particularly relates to the application of the mycoepoxydiene nicotinic acids derivatives in the preparation process of drugs that are used for treating inflammatory diseases such as endotoxin shocks which are mediated by inflammatory factors. The molecular formula of the mycoepoxydiene nicotinic acids derivatives is C19H19NO4. Pharmacology experiments prove that the mycoepoxydiene nicotinic acids derivatives can effectively inhibit the expression of the inflammatory factors such as tumor necrosis factor (TNF-Alpha), interleukin 6 (IL-6) and nitric monoxide (NO). The mycoepoxydiene nicotinic acids derivatives can be used for preparing the pro-inflammatory mediator inhibitors, especially, the mycoepoxydiene nicotinic acids derivatives can be used for preparing the drugs for treating inflammatory diseases such as endotoxin shocks which are mediated by inflammatory factors.
Owner:XIAMEN UNIV

Sense oligonucleotide capable of controlling the expression of inos and composition comprising the same

The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.
Owner:AMINO CHEM

Application of mycoepoxydiene nicotinic acids derivatives in preparation process of pro-inflammatory mediator inhibitors

The invention discloses the application of mycoepoxydiene nicotinic acids derivatives in the preparation process of pro-inflammatory mediator inhibitors, and relates to the mycoepoxydiene nicotinic acids derivatives 4-NDM (4-N Dodecyl Mercaptan). The provided application of the mycoepoxydiene nicotinic acids derivatives in the preparation process of the pro-inflammatory mediator inhibitors particularly relates to the application of the mycoepoxydiene nicotinic acids derivatives in the preparation process of drugs that are used for treating inflammatory diseases such as endotoxin shocks which are mediated by inflammatory factors. The molecular formula of the mycoepoxydiene nicotinic acids derivatives is C19H19NO4. Pharmacology experiments prove that the mycoepoxydiene nicotinic acids derivatives can effectively inhibit the expression of the inflammatory factors such as tumor necrosis factor (TNF-Alpha), interleukin 6 (IL-6) and nitric monoxide (NO). The mycoepoxydiene nicotinic acids derivatives can be used for preparing the pro-inflammatory mediator inhibitors, especially, the mycoepoxydiene nicotinic acids derivatives can be used for preparing the drugs for treating inflammatory diseases such as endotoxin shocks which are mediated by inflammatory factors.
Owner:XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products